ResMed | (RMD) — insider trading
Health Care · NYSE
ResMed | (RMD) has 35 reported SEC Form 4 insider transactions in our data, including 14 open-market sales among the most recent 35 (latest 2026-10-07).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-07 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Option exercise / conversion (derivative) | 4,991 | — | $0 | Form 4 |
| 2026-10-07 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Open-market sale | 4,991 | $226.33 | $1.13M | Form 4 |
| 2026-10-07 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Option exercise / conversion | 4,991 | $146.34 | $730.4K | Form 4 |
| 2026-09-08 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Option exercise / conversion (derivative) | 4,991 | — | $0 | Form 4 |
| 2026-09-08 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Open-market sale | 4,991 | $222.44 | $1.11M | Form 4 |
| 2026-09-08 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Option exercise / conversion | 4,991 | $146.34 | $730.4K | Form 4 |
| 2026-09-02 | FARRELL PETER C | Director | Open-market sale | 970 | $234.73 | $227.7K | Form 4 |
| 2026-08-14 | Rider Michael J | Officer (Global General Counsel) | Grant / award / vesting | 3,230 | — | $0 | Form 4 |
| 2026-08-14 | Leong Justin | Officer (Chief Product Officer) | Grant / award / vesting | 6,461 | — | $0 | Form 4 |
| 2026-08-14 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Grant / award / vesting | 13,547 | — | $0 | Form 4 |
| 2026-08-14 | Bloomer Aaron | Officer (Chief Financial Officer) | Grant / award / vesting | 9,072 | — | $0 | Form 4 |
| 2026-08-07 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Option exercise / conversion (derivative) | 4,991 | — | $0 | Form 4 |
| 2026-08-07 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Open-market sale | 4,991 | $205.69 | $1.03M | Form 4 |
| 2026-08-07 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Option exercise / conversion | 4,991 | $146.34 | $730.4K | Form 4 |
| 2026-08-05 | FARRELL PETER C | Director | Open-market sale | 8,000 | $225.00 | $1.80M | Form 4 |
| 2026-07-07 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Option exercise / conversion (derivative) | 4,991 | — | $0 | Form 4 |
| 2026-07-07 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Open-market sale | 4,991 | $218.55 | $1.09M | Form 4 |
| 2026-07-07 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Option exercise / conversion | 4,991 | $146.34 | $730.4K | Form 4 |
| 2026-06-08 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Option exercise / conversion (derivative) | 4,991 | — | $0 | Form 4 |
| 2026-06-08 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Open-market sale | 4,991 | $193.96 | $968.1K | Form 4 |
| 2026-06-08 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Option exercise / conversion | 4,991 | $146.34 | $730.4K | Form 4 |
| 2026-06-01 | Rider Michael J | Officer (Global General Counsel) | Shares withheld for taxes / exercise cost | 269 | $190.57 | $51.2K | Form 4 |
| 2026-05-07 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Option exercise / conversion (derivative) | 4,991 | — | $0 | Form 4 |
| 2026-05-07 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Open-market sale | 4,991 | $207.82 | $1.04M | Form 4 |
| 2026-05-07 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Option exercise / conversion | 4,991 | $146.34 | $730.4K | Form 4 |
| 2026-04-07 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Option exercise / conversion (derivative) | 4,991 | — | $0 | Form 4 |
| 2026-04-07 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Open-market sale | 4,991 | $225.50 | $1.13M | Form 4 |
| 2026-04-07 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Option exercise / conversion | 4,991 | $146.34 | $730.4K | Form 4 |
| 2026-04-01 | Sandercock Brett | Officer (Chief Financial Officer) | Open-market sale | 1,000 | $224.31 | $224.3K | Form 4 |
| 2026-04-01 | FARRELL PETER C | Director | Open-market sale | 2,000 | $225.00 | $450.0K | Form 4 |
| 2026-03-09 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Option exercise / conversion (derivative) | 4,991 | — | $0 | Form 4 |
| 2026-03-09 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Open-market sale | 4,991 | $251.03 | $1.25M | Form 4 |
| 2026-03-09 | Farrell Michael J. | Director, Officer (Chairman and CEO) | Option exercise / conversion | 4,991 | $146.34 | $730.4K | Form 4 |
| 2026-03-04 | FARRELL PETER C | Director | Open-market sale | 2,000 | $260.22 | $520.4K | Form 4 |
| 2026-03-02 | Sandercock Brett | Officer (Chief Financial Officer) | Open-market sale | 1,000 | $254.30 | $254.3K | Form 4 |
Ask the chat about RMD's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ResMed | (RMD).
Last updated 2026-10-07 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.